clinical trial · NCT07050641
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
Sinocelltech Ltd.·phase2·recruiting·n = 110
Advanced Malignant Solid TumorSCTB39-1
brief summary
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39-1 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
started
Jun 23, 2025
primary completion
Jun 30, 2028
completion
Jun 30, 2028
last updated
Jul 4, 2025
official title
An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB39-1 in Adult Patients With Advanced Malignant Solid Tumours
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol